Baropharm, CHD Pharm Bring Pharmacy-Only Cosmeceutical REVICLE to Japan

CHD Pharm, a subsidiary of pharmacy AX platform company Baropharm, is entering the Japanese market with REVICLE, its cosmeceutical brand exclusively for pharmacies. After demonstrating the brand's product competitiveness in domestic pharmacy channels, the company plans to accelerate its overseas expansion, starting with Japan.

Baropharm announced on October 13 that REVICLE had officially entered ainz&tulpe, a Japanese beauty and drugstore select shop. Sales began on October 8 at major locations, including the Shinjuku store in Tokyo, and the company plans to expand distribution to around 80 ainz&tulpe stores across Japan.

REVICLE is a cosmeceutical brand exclusively for pharmacies, launched by CHD Pharm in January this year. Its first product, REVICLE RX PDRN EGF Cream, was supplied to more than 2,000 pharmacies nationwide within six months of its launch, quickly establishing a distribution network in the domestic market.

The product range is also expanding. The company broadened consumer choice by successively launching sunscreen, face masks, and a niacinamide product in July and August. Having gauged the response to its products in domestic pharmacy channels, the company plans to build the brand's competitiveness in overseas markets as well.

The Baropharm Group's business structure supports REVICLE's product development and distribution. CHD Pharm, a pharmaceutical manufacturer, develops products based on expertise accumulated through pharmaceutical development, while Baropharm uses pharmacy-specific ordering and sales data gathered through its pharmacy AX platform to plan and improve products. Actual distribution and sales are handled by Baropharm subsidiary BRP Labs.

In Japan, the company is targeting local consumers with the concept of a "K-Pharmacy derma brand." In addition to beginning sales through ainz&tulpe, it is discussing further listings with pharmacy chains and other retailers in Japan.

Preparations are also underway to enter the North American market. Baropharm has completed the listing of a REVICLE brand store in Amazon's K-Beauty section and integrated its logistics. The official brand store is scheduled to open this December. The company has also completed preparations for U.S. cosmetics regulations, including the FDA's Voluntary Cosmetic Registration Program (VCRP) and the Modernization of Cosmetics Regulation Act (MoCRA).

Baropharm plans to use its expanded distribution in Japan as a springboard to broaden REVICLE's presence to North America, Asia, and other markets, developing it into a global brand.

A Baropharm representative said, "It is meaningful that REVICLE, a brand validated by pharmacies, is now reaching Japanese consumers. Building on the track record we establish in Japan, we will expand into North America, Asia, and other markets and grow REVICLE into a global K-Pharmacy brand."

This content was produced with the assistance of AI translation services.